{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T04:36:09Z","timestamp":1781584569831,"version":"3.54.5"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,5,31]],"date-time":"2022-05-31T00:00:00Z","timestamp":1653955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,5,31]],"date-time":"2022-05-31T00:00:00Z","timestamp":1653955200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000060","name":"U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["5R44AI055229"],"award-info":[{"award-number":["5R44AI055229"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["npj Vaccines"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Repeated direct venous inoculation of <jats:italic>Plasmodium falciparum<\/jats:italic> sporozoites (PfSPZ) together with antimalarial chemoprophylaxis (PfSPZ\u2013CVac) is the most potent way to induce sterile immunity against <jats:italic>P. falciparum<\/jats:italic> infection in malaria-naive volunteers. However, established schedules are complex and long. Here, we tested two accelerated three-dose schedules (28- and 10-day regimen) assessing efficacy by controlled human malaria infection (CHMI) against placebo, comparing vaccine-specific T cell and antibody responses by antigen-reactive T cell enrichment (ARTE) and protein microarray, respectively. Both regimens were similarly efficacious (67 and 63% vaccine efficacy) but different in the induction of vaccine-specific T cells and antibodies. The 10-day regimen resulted in higher numbers of antigen-specific CD4+ effector memory pro-inflammatory T cells and a broader antibody response compared with the 28-day regimen. Usually in nature, <jats:italic>P. falciparum<\/jats:italic> liver stage lasts about 6.5 days. The short vaccination-interval of the 10-day regimen prolongs the time of continuous exposure to liver-stage parasites, which may explain the stronger response. Besides dose and number of vaccinations, duration of liver-stage exposure is a factor to optimize PfSPZ\u2013CVac immunogenicity.<\/jats:p>","DOI":"10.1038\/s41541-022-00473-1","type":"journal-article","created":{"date-parts":[[2022,5,31]],"date-time":"2022-05-31T10:03:42Z","timestamp":1653991422000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Efficacy, T cell activation and antibody responses in accelerated Plasmodium falciparum sporozoite chemoprophylaxis vaccine regimens"],"prefix":"10.1038","volume":"7","author":[{"given":"Javier","family":"Ibanez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4716-0311","authenticated-orcid":false,"given":"Rolf","family":"Fendel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7401-2720","authenticated-orcid":false,"given":"Freia-Raphaella","family":"Lorenz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia","family":"Granados-Bayon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sina","family":"Br\u00fcckner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meral","family":"Esen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mih\u00e1ly","family":"Sulyok","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zita","family":"Sulyok","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steffen","family":"Borrmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Petra","family":"Bacher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0626-343X","authenticated-orcid":false,"given":"Alexander","family":"Scheffold","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0700-9505","authenticated-orcid":false,"given":"Stephen L.","family":"Hoffman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3926-4113","authenticated-orcid":false,"given":"Peter G.","family":"Kremsner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9101-2768","authenticated-orcid":false,"given":"Benjamin","family":"Mordm\u00fcller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,5,31]]},"reference":[{"key":"473_CR1","unstructured":"World malaria report 2021. https:\/\/www.who.int\/teams\/global-malaria-programme\/reports\/world-malaria-report-2021 (2021)."},{"key":"473_CR2","unstructured":"World Health Organization & Global Malaria Programme. Global technical strategy for malaria, 2016\u20132030. (2015)."},{"key":"473_CR3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41541-020-0196-3","volume":"5","author":"PE Duffy","year":"2020","unstructured":"Duffy, P. E. & Patrick Gorres, J. Malaria vaccines since 2000: progress, priorities, products. npj Vaccines 5, 1\u20139 (2020).","journal-title":"npj Vaccines"},{"key":"473_CR4","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1097\/00000441-197309000-00002","volume":"266","author":"DF Clyde","year":"1973","unstructured":"Clyde, D. F., Most, H., McCarthy, V. C. & Vanderberg, J. P. Immunization of man against sporozite-induced falciparum malaria. Am. J. Med. Sci. 266, 169\u2013177 (1973).","journal-title":"Am. J. Med. Sci."},{"key":"473_CR5","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1016\/0035-9203(74)90129-1","volume":"68","author":"KH Rieckmann","year":"1974","unstructured":"Rieckmann, K. H., Carson, P. E., Beaudoin, R. L., Cassells, J. S. & Sell, K. W. Letter: sporozoite induced immunity in man against an Ethiopian strain of Plasmodium falciparum. Trans. R. Soc. Trop. Med. Hyg. 68, 258\u2013259 (1974).","journal-title":"Trans. R. Soc. Trop. Med. Hyg."},{"key":"473_CR6","doi-asserted-by":"publisher","unstructured":"Maxmen, A. Scientists hail historic malaria vaccine approval \u2014 but point to challenges ahead. Nature https:\/\/doi.org\/10.1038\/d41586-021-02755-5 (2021).","DOI":"10.1038\/d41586-021-02755-5"},{"key":"473_CR7","doi-asserted-by":"publisher","first-page":"e1003377","DOI":"10.1371\/journal.pmed.1003377","volume":"17","author":"AB Hogan","year":"2020","unstructured":"Hogan, A. B., Winskill, P. & Ghani, A. C. Estimated impact of RTS,S\/AS01 malaria vaccine allocation strategies in sub-Saharan Africa: A modelling study. PLoS Med. 17, e1003377 (2020).","journal-title":"PLoS Med."},{"key":"473_CR8","doi-asserted-by":"publisher","first-page":"7452","DOI":"10.1016\/j.vaccine.2015.09.096","volume":"33","author":"TL Richie","year":"2015","unstructured":"Richie, T. L. et al. Progress with Plasmodium falciparum sporozoite (PfSPZ)-based malaria vaccines. Vaccine 33, 7452\u20137461 (2015).","journal-title":"Vaccine"},{"key":"473_CR9","doi-asserted-by":"crossref","unstructured":"Lynen, G. et al. East Coast fever immunisation field trial in crossbred dairy cattle in Hanang and Handeni districts in northern Tanzania. Trop. Anim. Health Prod. 44, 567\u2013572 (2012).","DOI":"10.1007\/s11250-011-9936-8"},{"key":"473_CR10","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1038\/nature21060","volume":"542","author":"B Mordm\u00fcller","year":"2017","unstructured":"Mordm\u00fcller, B. et al. Sterile protection against human malaria by chemoattenuated PfSPZ vaccine. Nature 542, 445\u2013449 (2017).","journal-title":"Nature"},{"key":"473_CR11","doi-asserted-by":"publisher","first-page":"3967","DOI":"10.4049\/jimmunol.1202221","volume":"190","author":"P Bacher","year":"2013","unstructured":"Bacher, P. et al. Antigen-reactive T cell enrichment for direct, high-resolution analysis of the human naive and memory Th cell repertoire. J. Immunol. 190, 3967\u20133976 (2013).","journal-title":"J. Immunol."},{"key":"473_CR12","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1007\/s11046-017-0229-2","volume":"183","author":"A Scheffold","year":"2018","unstructured":"Scheffold, A., Schwarz, C. & Bacher, P. Fungus-specific CD4 T cells as specific sensors for identification of pulmonary fungal infections. Mycopathologia 183, 213\u2013226 (2018).","journal-title":"Mycopathologia"},{"key":"473_CR13","doi-asserted-by":"publisher","first-page":"1340","DOI":"10.1016\/j.cell.2019.01.041","volume":"176","author":"P Bacher","year":"2019","unstructured":"Bacher, P. et al. Human anti-fungal Th17 immunity and pathology rely on cross-reactivity against Candida albicans. Cell 176, 1340\u20131355.e15 (2019).","journal-title":"Cell"},{"key":"473_CR14","doi-asserted-by":"publisher","first-page":"1258","DOI":"10.1016\/j.immuni.2020.11.016","volume":"53","author":"P Bacher","year":"2020","unstructured":"Bacher, P. et al. Low-avidity CD4+ T cell responses to SARS-CoV-2 in unexposed individuals and humans with severe COVID-19. Immunity 53, 1258\u20131271.e5 (2020).","journal-title":"Immunity"},{"key":"473_CR15","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.1016\/j.cell.2016.09.050","volume":"167","author":"P Bacher","year":"2016","unstructured":"Bacher, P. et al. Regulatory T cell specificity directs tolerance versus allergy against aeroantigens in humans. Cell 167, 1067\u20131078.e16 (2016).","journal-title":"Cell"},{"key":"473_CR16","doi-asserted-by":"publisher","first-page":"40ra49","DOI":"10.1126\/scitranslmed.3001058","volume":"2","author":"J Friesen","year":"2010","unstructured":"Friesen, J. et al. Natural immunization against malaria: causal prophylaxis with antibiotics. Sci. Transl. Med. 2, 40ra49\u201340ra49 (2010).","journal-title":"Sci. Transl. Med."},{"key":"473_CR17","doi-asserted-by":"publisher","first-page":"1862","DOI":"10.1128\/AAC.38.8.1862","volume":"38","author":"SL Andersen","year":"1994","unstructured":"Andersen, S. L. et al. Efficacy of azithromycin as a causal prophylactic agent against murine malaria. Antimicrob. Agents Chemother. 38, 1862\u20131863 (1994).","journal-title":"Antimicrob. Agents Chemother."},{"key":"473_CR18","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-22740-w","volume":"12","author":"Z Sulyok","year":"2021","unstructured":"Sulyok, Z. et al. Heterologous protection against malaria by a simple chemoattenuated PfSPZ vaccine regimen in a randomized trial. Nat. Commun. 12, 2518 (2021).","journal-title":"Nat. Commun."},{"key":"473_CR19","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1097\/00000441-197312000-00001","volume":"266","author":"DF Clyde","year":"1973","unstructured":"Clyde, D. F., McCarthy, V. C., Miller, R. M. & Hornick, R. B. Specificity of protection of man immunized against sporozoite-induced falciparum malaria. Am. J. Med. Sci. 266, 398\u2013403 (1973).","journal-title":"Am. J. Med. Sci."},{"key":"473_CR20","doi-asserted-by":"publisher","first-page":"2748","DOI":"10.3389\/fimmu.2018.02748","volume":"9","author":"LS Itsara","year":"2018","unstructured":"Itsara, L. S. et al. The development of whole sporozoite vaccines for Plasmodium falciparum malaria. Front. Immunol. 9, 2748 (2018).","journal-title":"Front. Immunol."},{"key":"473_CR21","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.3389\/fimmu.2019.01227","volume":"10","author":"YS Goh","year":"2019","unstructured":"Goh, Y. S., McGuire, D. & R\u00e9nia, L. Vaccination with sporozoites: models and correlates of protection. Front Immunol. 10, 1227 (2019).","journal-title":"Front Immunol."},{"key":"473_CR22","doi-asserted-by":"publisher","first-page":"97","DOI":"10.4161\/hv.6.1.10396","volume":"6","author":"SL Hoffman","year":"2010","unstructured":"Hoffman, S. L. et al. Development of a metabolically active, non-replicating sporozoite vaccine to prevent Plasmodium falciparum malaria. Hum. Vaccin. 6, 97\u2013106 (2010).","journal-title":"Hum. Vaccin."},{"key":"473_CR23","doi-asserted-by":"publisher","first-page":"e89154","DOI":"10.1172\/jci.insight.89154","volume":"2","author":"JE Epstein","year":"2017","unstructured":"Epstein, J. E. et al. Protection against Plasmodium falciparum malaria by PfSPZ Vaccine. JCI Insight 2, e89154 (2017).","journal-title":"JCI Insight"},{"key":"473_CR24","doi-asserted-by":"publisher","first-page":"2711","DOI":"10.1073\/pnas.1615324114","volume":"114","author":"KE Lyke","year":"2017","unstructured":"Lyke, K. E. et al. Attenuated PfSPZ Vaccine induces strain-transcending T cells and durable protection against heterologous controlled human malaria infection. Proc. Natl Acad. Sci. USA 114, 2711\u20132716 (2017).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"473_CR25","doi-asserted-by":"publisher","first-page":"308","DOI":"10.4269\/ajtmh.17-0449","volume":"98","author":"A Olotu","year":"2018","unstructured":"Olotu, A. et al. Advancing global health through development and clinical trials partnerships: a randomized, placebo-controlled, double-blind assessment of safety, tolerability, and immunogenicity of PfSPZ vaccine for malaria in healthy Equatoguinean men. Am. J. Trop. Med. Hyg. 98, 308\u2013318 (2018).","journal-title":"Am. J. Trop. Med. Hyg."},{"key":"473_CR26","doi-asserted-by":"publisher","first-page":"1433","DOI":"10.4269\/ajtmh.18-0835","volume":"100","author":"SA Jongo","year":"2019","unstructured":"Jongo, S. A. et al. Safety and differential antibody and T-cell responses to the Plasmodium falciparum sporozoite malaria vaccine, PfSPZ vaccine, by age in Tanzanian adults, adolescents, children, and infants. Am. J. Trop. Med. Hyg. 100, 1433\u20131444 (2019).","journal-title":"Am. J. Trop. Med. Hyg."},{"key":"473_CR27","doi-asserted-by":"publisher","first-page":"2849","DOI":"10.1093\/cid\/ciz1152","volume":"71","author":"SA Jongo","year":"2020","unstructured":"Jongo, S. A. et al. Increase of dose associated with decrease in protection against controlled human malaria infection by PfSPZ vaccine in Tanzanian adults. Clin. Infect. Dis. 71, 2849\u20132857 (2020).","journal-title":"Clin. Infect. Dis."},{"key":"473_CR28","doi-asserted-by":"publisher","first-page":"1481","DOI":"10.1093\/cid\/ciz1010","volume":"71","author":"SA Healy","year":"2020","unstructured":"Healy, S. A. et al. Chemoprophylaxis vaccination: phase I study to explore stage-specific immunity to Plasmodium falciparum in US adults. Clin. Infect. Dis. 71, 1481\u20131490 (2020).","journal-title":"Clin. Infect. Dis."},{"key":"473_CR29","doi-asserted-by":"publisher","first-page":"283","DOI":"10.4269\/ajtmh.20-0435","volume":"104","author":"SA Jongo","year":"2021","unstructured":"Jongo, S. A. et al. Immunogenicity and protective efficacy of radiation-attenuated and chemo-attenuated PfSPZ vaccines in equatoguinean adults. Am. J. Trop. Med. Hyg. 104, 283\u2013293 (2021).","journal-title":"Am. J. Trop. Med. Hyg."},{"key":"473_CR30","doi-asserted-by":"crossref","unstructured":"Roestenberg, M. et al. A double-blind, placebo-controlled phase 1\/2a trial of the genetically attenuated malaria vaccine PfSPZ-GA1. Sci. Transl. Med. 12, eaaz5629 (2020).","DOI":"10.1126\/scitranslmed.aaz5629"},{"key":"473_CR31","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1126\/science.102.2643.202","volume":"102","author":"J Freund","year":"1945","unstructured":"Freund, J., Thomson, K. J., Sommer, H. E., Walter, A. W. & Schenkein, E. L. Immunization of rhesus monkeys against malarial infection (p. knowlesi) with killed parasites and adjuvants. Science 102, 202\u2013204 (1945).","journal-title":"Science"},{"key":"473_CR32","doi-asserted-by":"publisher","first-page":"2487","DOI":"10.4049\/jimmunol.172.4.2487","volume":"172","author":"E Belnoue","year":"2004","unstructured":"Belnoue, E. et al. Protective T cell immunity against malaria liver stage after vaccination with live sporozoites under chloroquine treatment. J. Immunol. 172, 2487\u20132495 (2004).","journal-title":"J. Immunol."},{"key":"473_CR33","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/0014-4894(77)90054-6","volume":"42","author":"RL Beaudoin","year":"1977","unstructured":"Beaudoin, R. L., Strome, C. P., Mitchell, F. & Tubergen, T. A. Plasmodium berghei: immunization of mice against the ANKA strain using the unaltered sporozoite as an antigen. Exp. Parasitol. 42, 1\u20135 (1977).","journal-title":"Exp. Parasitol."},{"key":"473_CR34","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1056\/NEJMoa0805832","volume":"361","author":"M Roestenberg","year":"2009","unstructured":"Roestenberg, M. et al. Protection against a malaria challenge by sporozoite inoculation. N. Engl. J. Med. 361, 468\u2013477 (2009).","journal-title":"N. Engl. J. Med."},{"key":"473_CR35","doi-asserted-by":"publisher","first-page":"e1009594","DOI":"10.1371\/journal.ppat.1009594","volume":"17","author":"SC Murphy","year":"2021","unstructured":"Murphy, S. C. et al. PfSPZ-CVac efficacy against malaria increases from 0% to 75% when administered in the absence of erythrocyte stage parasitemia: a randomized, placebo-controlled trial with controlled human malaria infection. PLoS Pathog. 17, e1009594 (2021).","journal-title":"PLoS Pathog."},{"key":"473_CR36","first-page":"47","volume":"65","author":"LA Salako","year":"1987","unstructured":"Salako, L. A., Aderounmu, A. F. & Walker, O. Influence of route of administration on the pharmacokinetics of chloroquine and desethylchloroquine. Bull. World Health Organ. 65, 47\u201350 (1987).","journal-title":"Bull. World Health Organ."},{"key":"473_CR37","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1111\/j.1365-2125.1986.tb02876.x","volume":"22","author":"S Looareesuwan","year":"1986","unstructured":"Looareesuwan, S. et al. Cardiovascular toxicity and distribution kinetics of intravenous chloroquine. Br. J. Clin. Pharm. 22, 31\u201336 (1986).","journal-title":"Br. J. Clin. Pharm."},{"key":"473_CR38","doi-asserted-by":"publisher","unstructured":"Mwakingwe-Omari, A. et al. Two chemoattenuated PfSPZ malaria vaccines induce sterile hepatic immunity. Nature https:\/\/doi.org\/10.1038\/s41586-021-03684-z (2021).","DOI":"10.1038\/s41586-021-03684-z"},{"key":"473_CR39","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-019-45440-4","volume":"9","author":"JS Eacret","year":"2019","unstructured":"Eacret, J. S., Gonzales, D. M., Franks, R. G. & Burns, J. M. Immunization with merozoite surface protein 2 fused to a Plasmodium-specific carrier protein elicits strain-specific and strain-transcending, opsonizing antibody. Sci. Rep. 9, 9022 (2019).","journal-title":"Sci. Rep."},{"key":"473_CR40","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1111\/j.1365-2125.1994.tb04363.x","volume":"38","author":"L Hermans","year":"1994","unstructured":"Hermans, L. et al. At equipotent doses, isradipine is better tolerated than amlodipine in patients with mild-to-moderate hypertension: a double-blind, randomized, parallel-group study. Br. J. Clin. Pharm 38, 335\u2013340 (1994).","journal-title":"Br. J. Clin. Pharm"},{"key":"473_CR41","doi-asserted-by":"publisher","DOI":"10.1038\/srep39462","volume":"6","author":"DJ Maskus","year":"2016","unstructured":"Maskus, D. J. et al. Characterization of a novel inhibitory human monoclonal antibody directed against Plasmodium falciparum apical membrane antigen 1. Sci. Rep. 6, 39462 (2016).","journal-title":"Sci. Rep."},{"key":"473_CR42","doi-asserted-by":"publisher","unstructured":"Taghavian, O. et al. Antibody profiling by proteome microarray with multiplex isotype detection reveals overlap between human and Aotus nancymaae controlled malaria infections. Proteomics, https:\/\/doi.org\/10.1002\/pmic.201700277 (2018).","DOI":"10.1002\/pmic.201700277"},{"key":"473_CR43","doi-asserted-by":"crossref","unstructured":"Kobayashi, T. et al. Distinct antibody signatures associated with different malaria transmission intensities in Zambia and Zimbabwe. mSphere 4, e00061-19 (2019).","DOI":"10.1128\/mSphereDirect.00061-19"},{"key":"473_CR44","doi-asserted-by":"publisher","unstructured":"Obiero, J. M. et al. Antibody biomarkers associated with sterile protection induced by controlled human malaria infection under chloroquine prophylaxis. mSphere, https:\/\/doi.org\/10.1002\/pmic.201700277 (2019).","DOI":"10.1002\/pmic.201700277"},{"key":"473_CR45","doi-asserted-by":"publisher","first-page":"4680","DOI":"10.1002\/pmic.200800194","volume":"8","author":"DL Doolan","year":"2008","unstructured":"Doolan, D. L. et al. Profiling humoral immune responses to P. falciparum infection with protein microarrays. Proteomics 8, 4680\u20134694 (2008).","journal-title":"Proteomics"},{"key":"473_CR46","doi-asserted-by":"publisher","first-page":"2700","DOI":"10.1093\/bioinformatics\/btm412","volume":"23","author":"ME Ritchie","year":"2007","unstructured":"Ritchie, M. E. et al. A comparison of background correction methods for two-colour microarrays. Bioinformatics 23, 2700\u20132707 (2007).","journal-title":"Bioinformatics"},{"key":"473_CR47","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1093\/biostatistics\/kxn042","volume":"10","author":"JD Silver","year":"2009","unstructured":"Silver, J. D., Ritchie, M. E. & Smyth, G. K. Microarray background correction: maximum likelihood estimation for the normal-exponential convolution. Biostatistics 10, 352\u2013363 (2009).","journal-title":"Biostatistics"},{"key":"473_CR48","doi-asserted-by":"publisher","first-page":"e47","DOI":"10.1093\/nar\/gkv007","volume":"43","author":"ME Ritchie","year":"2015","unstructured":"Ritchie, M. E. et al. limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res. 43, e47 (2015).","journal-title":"Nucleic Acids Res."}],"container-title":["npj Vaccines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41541-022-00473-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41541-022-00473-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41541-022-00473-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,24]],"date-time":"2022-11-24T18:42:46Z","timestamp":1669315366000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41541-022-00473-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,31]]},"references-count":48,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["473"],"URL":"https:\/\/doi.org\/10.1038\/s41541-022-00473-1","relation":{},"ISSN":["2059-0105"],"issn-type":[{"value":"2059-0105","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,5,31]]},"assertion":[{"value":"6 October 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 March 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 May 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"BM and PGK received funding from the DZIF. SLH, associated with Sanaria Inc., has a potential conflict of interest. All other authors declare no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"59"}}